EDUCATION

Medical School

  • Dartmouth Medical School , 1998 , Hanover , NH

Internship

  • Mt. Auburn Hospital , 1999 , Cambridge , MA

Residency

  • Massachusetts General and McLean Hospitals , 2001 , Boston , MA

Fellowship

  • Massachusetts General and McLean Hospitals , 2003 , Boston , MA

CERTIFICATIONS

  • American Board of Psychiatry and Neurology, Psychiatry
  • American Board of Psychiatry and Neurology, Child and Adolescent Psychiatry

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Hauptman AJ, Acar D, Hammerness P, Fogler JM, Stafford D. A Case of Emotional Trauma in the Setting of Neurodevelopmental Disability. Harv Rev Psychiatry. 2018 Nov/Dec; 26(6):384-391. View abstract
  2. Biederman J, Hammerness P, Sadeh B, Peremen Z, Amit A, Or-Ly H, Stern Y, Reches A, Geva A, Faraone SV. Diagnostic utility of brain activity flow patterns analysis in attention deficit hyperactivity disorder. Psychol Med. 2017 May; 47(7):1259-1270. View abstract
  3. Hammerness P, Petty C, Faraone SV, Biederman J. Do Stimulants Reduce the Risk for Alcohol and Substance Use in Youth With ADHD? A Secondary Analysis of a Prospective, 24-Month Open-Label Study of Osmotic-Release Methylphenidate. J Atten Disord. 2017 01; 21(1):71-77. View abstract
  4. Chan E, Fogler JM, Hammerness PG. Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review. JAMA. 2016 May 10; 315(18):1997-2008. View abstract
  5. Sprich SE, Safren SA, Finkelstein D, Remmert JE, Hammerness P. A randomized controlled trial of cognitive behavioral therapy for ADHD in medication-treated adolescents. J Child Psychol Psychiatry. 2016 11; 57(11):1218-1226. View abstract
  6. Hammerness PG, Karampahtsis C, Babalola R, Alexander ME. Attention-deficit/hyperactivity disorder treatment: what are the long-term cardiovascular risks? Expert Opin Drug Saf. 2015 Apr; 14(4):543-51. View abstract
  7. Faraone SV, Hammerness PG, Wilens TE. Reliability and Validity of the Before-School Functioning Scale in Children With ADHD. J Atten Disord. 2018 Sep; 22(11):1040-1048. View abstract
  8. Munshi K, Alexander ME, Hammerness P. Corrected QT interval changes with atypical antipsychotics. J Am Acad Child Adolesc Psychiatry. 2015 Jan; 54(1):9-10. View abstract
  9. Ulbricht C, Basch E, Cheung L, Goldberg H, Hammerness P, Isaac R, Khalsa KP, Romm A, Rychlik I, Varghese M, Weissner W, Windsor RC, Wortley J. An evidence-based systematic review of elderberry and elderflower (Sambucus nigra) by the Natural Standard Research Collaboration. J Diet Suppl. 2014 Mar; 11(1):80-120. View abstract
  10. Hammerness P, Fried R, Petty C, Meller B, Biederman J. Assessment of cognitive domains during treatment with OROS methylphenidate in adolescents with ADHD. Child Neuropsychol. 2014; 20(3):319-27. View abstract
  11. Biederman J, Pettye CR, Hammerness P, Woodworth KY, Faraon SV. Examining the nature of the association between attention-deficit hyperactivity disorder and nicotine dependence: a familial risk analysis. Can J Psychiatry. 2013 Mar; 58(3):177-83. View abstract
  12. Surman CB, Hammerness PG, Pion K, Faraone SV. Do stimulants improve functioning in adults with ADHD? A review of the literature. Eur Neuropsychopharmacol. 2013 Jun; 23(6):528-33. View abstract
  13. Ulbricht C, Basch E, Chao W, Conquer J, Costa D, Culwell S, Flanagan K, Guilford J, Hammerness P, Hashmi S, Isaac R, Rusie E, Serrano JM, Ulbricht C, Vora M, Windsor RC, Woloszyn M, Zhou S. An evidence-based systematic review of vitamin A by the natural standard research collaboration. J Diet Suppl. 2012 Dec; 9(4):299-416. View abstract
  14. Hammerness P, Joshi G, Doyle R, Georgiopoulos A, Geller D, Spencer T, Petty CR, Faraone SV, Biederman J. Do stimulants reduce the risk for cigarette smoking in youth with attention-deficit hyperactivity disorder? A prospective, long-term, open-label study of extended-release methylphenidate. J Pediatr. 2013 Jan; 162(1):22-7.e2. View abstract
  15. Biederman J, Petty CR, Hammerness P, Batchelder H, Faraone SV. Cigarette smoking as a risk factor for other substance misuse: 10-year study of individuals with and without attention-deficit hyperactivity disorder. Br J Psychiatry. 2012 Sep; 201(3):207-14. View abstract
  16. Fried R, Surman C, Hammerness P, Petty C, Faraone S, Hyder L, Westerberg D, Small J, Corkum L, Claudat K, Biederman J. A controlled study of a simulated workplace laboratory for adults with attention deficit hyperactivity disorder. Psychiatry Res. 2012 Dec 30; 200(2-3):949-56. View abstract
  17. Hammerness P, Zusman R, Systrom D, Surman C, Baggish A, Schillinger M, Shelley-Abrahamson R, Wilens TE. A cardiopulmonary study of lisdexamfetamine in adults with attention-deficit/hyperactivity disorder. World J Biol Psychiatry. 2013 May; 14(4):299-306. View abstract
  18. Adler LA, Shaw DM, Spencer TJ, Newcorn JH, Hammerness P, Sitt DJ, Minerly C, Davidow JV, Faraone SV. Preliminary examination of the reliability and concurrent validity of the attention-deficit/hyperactivity disorder self-report scale v1.1 symptom checklist to rate symptoms of attention-deficit/hyperactivity disorder in adolescents. J Child Adolesc Psychopharmacol. 2012 Jun; 22(3):238-44. View abstract
  19. Biederman J, Fried R, Hammerness P, Surman C, Mehler B, Petty CR, Faraone SV, Miller C, Bourgeois M, Meller B, Godfrey KM, Baer L, Reimer B. The effects of lisdexamfetamine dimesylate on driving behaviors in young adults with ADHD assessed with the Manchester driving behavior questionnaire. J Adolesc Health. 2012 Dec; 51(6):601-7. View abstract
  20. Surman CB, Hammerness PG, Petty C, Spencer T, Doyle R, Napolean S, Chu N, Yorks D, Biederman J. A pilot open label prospective study of memantine monotherapy in adults with ADHD. World J Biol Psychiatry. 2013 May; 14(4):291-8. View abstract
  21. Biederman J, Fried R, Hammerness P, Surman C, Mehler B, Petty CR, Faraone SV, Miller C, Bourgeois M, Meller B, Godfrey KM, Reimer B. The effects of lisdexamfetamine dimesylate on the driving performance of young adults with ADHD: a randomized, double-blind, placebo-controlled study using a validated driving simulator paradigm. J Psychiatr Res. 2012 Apr; 46(4):484-91. View abstract
  22. Wozniak J, Gönenç A, Biederman J, Moore C, Joshi G, Georgiopoulos A, Hammerness P, McKillop H, Lukas SE, Henin A. A magnetic resonance spectroscopy study of the anterior cingulate cortex in youth with emotional dysregulation. Isr J Psychiatry Relat Sci. 2012; 49(1):62-9. View abstract
  23. Joshi G, Petty C, Wozniak J, Faraone SV, Doyle R, Georgiopoulos A, Hammerness P, Walls S, Glaeser B, Brethel K, Yorks D, Biederman J. A prospective open-label trial of quetiapine monotherapy in preschool and school age children with bipolar spectrum disorder. J Affect Disord. 2012 Feb; 136(3):1143-53. View abstract
  24. Hammerness PG, Surman CB, Chilton A. Adult attention-deficit/hyperactivity disorder treatment and cardiovascular implications. Curr Psychiatry Rep. 2011 Oct; 13(5):357-63. View abstract
  25. Hammerness PG, Perrin JM, Shelley-Abrahamson R, Wilens TE. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations. J Am Acad Child Adolesc Psychiatry. 2011 Oct; 50(10):978-90. View abstract
  26. Ulbricht C, Abrams TR, Basch E, Davies-Heerema T, Foppa I, Hammerness P, Rusie E, Tanguay-Colucci S, Taylor S, Ulbricht C, Varghese M, Weissner W, Woods J. An evidence-based systematic review of gymnema (Gymnema sylvestre R. Br.) by the Natural Standard Research Collaboration. J Diet Suppl. 2011 Sep; 8(3):311-30. View abstract
  27. Hammerness P, Biederman J, Petty C, Henin A, Moore CM. Brain biochemical effects of methylphenidate treatment using proton magnetic spectroscopy in youth with attention-deficit hyperactivity disorder: a controlled pilot study. CNS Neurosci Ther. 2012 Jan; 18(1):34-40. View abstract
  28. Joshi G, Biederman J, Wozniak J, Doyle R, Hammerness P, Galdo M, Sullivan N, Williams C, Brethel K, Woodworth KY, Mick E. Response to second generation antipsychotics in youth with comorbid bipolar disorder and autism spectrum disorder. CNS Neurosci Ther. 2012 Jan; 18(1):28-33. View abstract
  29. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Kotarski M, Spencer T. A randomized, 3-phase, 34-week, double-blind, long-term efficacy study of osmotic-release oral system-methylphenidate in adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol. 2010 Oct; 30(5):549-53. View abstract
  30. Spencer TJ, Mick E, Surman CB, Hammerness P, Doyle R, Aleardi M, Kotarski M, Williams CG, Biederman J. A randomized, single-blind, substitution study of OROS methylphenidate (Concerta) in ADHD adults receiving immediate release methylphenidate. J Atten Disord. 2011 May; 15(4):286-94. View abstract
  31. Wilens TE, Hammerness P, Martelon M, Brodziak K, Utzinger L, Wong P. A controlled trial of the methylphenidate transdermal system on before-school functioning in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2010 May; 71(5):548-56. View abstract
  32. Biederman J, Joshi G, Mick E, Doyle R, Georgiopoulos A, Hammerness P, Kotarski M, Williams C, Wozniak J. A prospective open-label trial of lamotrigine monotherapy in children and adolescents with bipolar disorder. CNS Neurosci Ther. 2010 Apr; 16(2):91-102. View abstract
  33. Joshi G, Wozniak J, Mick E, Doyle R, Hammerness P, Georgiopoulos A, Kotarski M, Aleardi M, Williams C, Walls S, Biederman J. A prospective open-label trial of extended-release carbamazepine monotherapy in children with bipolar disorder. J Child Adolesc Psychopharmacol. 2010 Feb; 20(1):7-14. View abstract
  34. Surman C, Hammerness P, Petty C, Doyle R, Chu N, Gebhard N, Williams C, Biederman J. Atomoxetine in the treatment of adults with subthreshold and/or late onset attention-deficit hyperactivity disorder-not otherwise specified (ADHD-NOS): a prospective open-label 6-week study. CNS Neurosci Ther. 2010; 16(1):6-12. View abstract
  35. Hammerness P, Georgiopoulos A, Doyle RL, Utzinger L, Schillinger M, Martelon M, Brodziak K, Biederman J, Wilens TE. An open study of adjunct OROS-methylphenidate in children who are atomoxetine partial responders: II. Tolerability and pharmacokinetics. J Child Adolesc Psychopharmacol. 2009 Oct; 19(5):493-9. View abstract
  36. Wilens TE, Hammerness P, Utzinger L, Schillinger M, Georgiopoulous A, Doyle RL, Martelon M, Brodziak K. An open study of adjunct OROS-methylphenidate in children and adolescents who are atomoxetine partial responders: I. Effectiveness. J Child Adolesc Psychopharmacol. 2009 Oct; 19(5):485-92. View abstract
  37. Hammerness P, Geller D, Petty C, Lamb A, Bristol E, Biederman J. Does ADHD moderate the manifestation of anxiety disorders in children? Eur Child Adolesc Psychiatry. 2010 Feb; 19(2):107-12. View abstract
  38. Hammerness P, Wilens T, Mick E, Spencer T, Doyle R, McCreary M, Becker J, Biederman J. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder. J Pediatr. 2009 Jul; 155(1):84-9, 89.e1. View abstract
  39. Hammerness P, Doyle R, Kotarski M, Georgiopoulos A, Joshi G, Zeitlin S, Biederman J. Atomoxetine in children with attention-deficit hyperactivity disorder with prior stimulant therapy: a prospective open-label study. Eur Child Adolesc Psychiatry. 2009 Aug; 18(8):493-8. View abstract
  40. Hammerness P, McCarthy K, Mancuso E, Gendron C, Geller D. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review. Neuropsychiatr Dis Treat. 2009; 5:215-26. View abstract
  41. Ulbricht C, Weissner W, Hashmi S, Rae Abrams T, Dacey C, Giese N, Hammerness P, Hackman DA, Kim J, Nealon A, Voloshin R. Essiac: systematic review by the natural standard research collaboration. J Soc Integr Oncol. 2009; 7(2):73-80. View abstract
  42. Ulbricht C, Weissner W, Basch E, Giese N, Hammerness P, Rusie-Seamon E, Varghese M, Woods J. Maitake mushroom (Grifola frondosa): systematic review by the natural standard research collaboration. J Soc Integr Oncol. 2009; 7(2):66-72. View abstract
  43. Hammerness P, Surman C, Miller K. Update on adult attention-deficit/hyperactivity disorder. Curr Neurol Neurosci Rep. 2008 Nov; 8(6):484-9. View abstract
  44. Monuteaux MC, Faraone SV, Hammerness P, Wilens TE, Fraire M, Biederman J. The familial association between cigarette smoking and ADHD: a study of clinically referred girls with and without ADHD, and their families. Nicotine Tob Res. 2008 Oct; 10(10):1549-58. View abstract
  45. Hammerness PG, Wilens TE, Berul CI, Elkort MS. Supraventricular tachycardia in an adolescent with attention-deficit/hyperactivity disorder (ADHD). J Am Acad Child Adolesc Psychiatry. 2008 Feb; 47(2):219-20. View abstract
  46. Biederman J, Hammerness P, Doyle R, Joshi G, Aleardi M, Mick E. Risperidone treatment for ADHD in children and adolescents with bipolar disorder. Neuropsychiatr Dis Treat. 2008 Feb; 4(1):203-7. View abstract
  47. Biederman J, Makris N, Valera EM, Monuteaux MC, Goldstein JM, Buka S, Boriel DL, Bandyopadhyay S, Kennedy DN, Caviness VS, Bush G, Aleardi M, Hammerness P, Faraone SV, Seidman LJ. Towards further understanding of the co-morbidity between attention deficit hyperactivity disorder and bipolar disorder: a MRI study of brain volumes. Psychol Med. 2008 Jul; 38(7):1045-56. View abstract
  48. Biederman J, Mick EO, Surman C, Doyle R, Hammerness P, Michel E, Martin J, Spencer TJ. Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. BMC Psychiatry. 2007 Sep 14; 7:49. View abstract
  49. Biederman J, Mick E, Spencer T, Doyle R, Joshi G, Hammerness P, Kotarski M, Aleardi M, Wozniak J. An open-label trial of aripiprazole monotherapy in children and adolescents with bipolar disorder. CNS Spectr. 2007 Sep; 12(9):683-9. View abstract
  50. Harpold T, Biederman J, Gignac M, Hammerness P, Surman C, Potter A, Mick E. Is oppositional defiant disorder a meaningful diagnosis in adults? Results from a large sample of adults with ADHD. J Nerv Ment Dis. 2007 Jul; 195(7):601-5. View abstract
  51. Hammerness P, Harpold T, Petty C, Menard C, Zar-Kessler C, Biederman J. Characterizing non-OCD anxiety disorders in psychiatrically referred children and adolescents. J Affect Disord. 2008 Jan; 105(1-3):213-9. View abstract
  52. Ulbricht C, Armstrong J, Basch E, Basch S, Bent S, Dacey C, Dalton S, Foppa I, Giese N, Hammerness P, Kirkwood C, Sollars D, Tanguay-Colucci S, Weissner W. An evidence-based systematic review of Aloe vera by the natural standard research collaboration. J Herb Pharmacother. 2007; 7(3-4):279-323. View abstract
  53. Ulbricht C, Basch E, Burke D, Cheung L, Ernst E, Giese N, Foppa I, Hammerness P, Hashmi S, Kuo G, Miranda M, Mukherjee S, Smith M, Sollars D, Tanguay-Colucci S, Vijayan N, Weissner W. Fenugreek (Trigonella foenum-graecum L. Leguminosae): an evidence-based systematic review by the natural standard research collaboration. J Herb Pharmacother. 2007; 7(3-4):143-77. View abstract
  54. Basch E, Bent S, Collins J, Dacey C, Hammerness P, Harrison M, Smith M, Szapary P, Ulbricht C, Vora M, Weissner W. Flax and flaxseed oil (Linum usitatissimum): a review by the Natural Standard Research Collaboration. J Soc Integr Oncol. 2007; 5(3):92-105. View abstract
  55. Moore CM, Biederman J, Wozniak J, Mick E, Aleardi M, Wardrop M, Dougherty M, Harpold T, Hammerness P, Randall E, Lyoo IK, Renshaw PF. Mania, glutamate/glutamine and risperidone in pediatric bipolar disorder: a proton magnetic resonance spectroscopy study of the anterior cingulate cortex. J Affect Disord. 2007 Apr; 99(1-3):19-25. View abstract
  56. Biederman J, Mick E, Spencer T, Surman C, Hammerness P, Doyle R, Dougherty M, Aleardi M, Schweitzer K. An open-label trial of OROS methylphenidate in adults with late-onset ADHD. CNS Spectr. 2006 May; 11(5):390-6. View abstract
  57. Wilens TE, Zusman RM, Hammerness PG, Podolski A, Whitley J, Spencer TJ, Gignac M, Biederman J. An open-label study of the tolerability of mixed amphetamine salts in adults with attention-deficit/hyperactivity disorder and treated primary essential hypertension. J Clin Psychiatry. 2006 May; 67(5):696-702. View abstract
  58. Biederman J, Mick E, Faraone S, Hammerness P, Surman C, Harpold T, Dougherty M, Aleardi M, Spencer T. A double-blind comparison of galantamine hydrogen bromide and placebo in adults with attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychopharmacol. 2006 Apr; 26(2):163-6. View abstract
  59. Hammerness PG, Vivas FM, Geller DA. Selective serotonin reuptake inhibitors in pediatric psychopharmacology: a review of the evidence. J Pediatr. 2006 Feb; 148(2):158-65. View abstract
  60. Moore CM, Biederman J, Wozniak J, Mick E, Aleardi M, Wardrop M, Dougherty M, Harpold T, Hammerness P, Randall E, Renshaw PF. Differences in brain chemistry in children and adolescents with attention deficit hyperactivity disorder with and without comorbid bipolar disorder: a proton magnetic resonance spectroscopy study. Am J Psychiatry. 2006 Feb; 163(2):316-8. View abstract
  61. Ulbricht C, Basch E, Bent S, Boon H, Corrado M, Foppa I, Hashmi S, Hammerness P, Kingsbury E, Smith M, Szapary P, Vora M, Weissner W. Evidence-based systematic review of saw palmetto by the Natural Standard Research Collaboration. J Soc Integr Oncol. 2006; 4(4):170-86. View abstract
  62. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, Dunkel S, Dougherty M, Aleardi M, Spencer T. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006 May 01; 59(9):829-35. View abstract
  63. Biederman J, Mick E, Hammerness P, Harpold T, Aleardi M, Dougherty M, Wozniak J. Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry. 2005 Oct 01; 58(7):589-94. View abstract
  64. Ulbricht C, Basch E, Szapary P, Hammerness P, Axentsev S, Boon H, Kroll D, Garraway L, Vora M, Woods J. Guggul for hyperlipidemia: a review by the Natural Standard Research Collaboration. Complement Ther Med. 2005 Dec; 13(4):279-90. View abstract
  65. Ulbricht C, Basch E, Boon H, Ernst E, Hammerness P, Sollars D, Tsourounis C, Woods J, Bent S. Safety review of kava (Piper methysticum) by the Natural Standard Research Collaboration. Expert Opin Drug Saf. 2005 Jul; 4(4):779-94. View abstract
  66. Wilens TE, Hammerness PG, Biederman J, Kwon A, Spencer TJ, Clark S, Scott M, Podolski A, Ditterline JW, Morris MC, Moore H. Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2005 Feb; 66(2):253-9. View abstract
  67. Hammerness P, Monuteaux MC, Faraone SV, Gallo L, Murphy H, Biederman J. Reexamining the familial association between asthma and ADHD in girls. J Atten Disord. 2005 Feb; 8(3):136-43. View abstract
  68. Ulbricht C, Basch E, Hammerness P, Vora M, Wylie J, Woods J. An evidence-based systematic review of belladonna by the natural standard research collaboration. J Herb Pharmacother. 2004; 4(4):61-90. View abstract
  69. Basch E, Ulbricht C, Hammerness P, Bevins A, Sollars D. Thyme (Thymus vulgaris L.), thymol. J Herb Pharmacother. 2004; 4(1):49-67. View abstract
  70. Hammerness P, Basch E, Ulbricht C, Barrette EP, Foppa I, Basch S, Bent S, Boon H, Ernst E. St John's wort: a systematic review of adverse effects and drug interactions for the consultation psychiatrist. Psychosomatics. 2003 Jul-Aug; 44(4):271-82. View abstract
  71. Wilens TE, Prince JB, Spencer T, Van Patten SL, Doyle R, Girard K, Hammerness P, Goldman S, Brown S, Biederman J. An open trial of bupropion for the treatment of adults with attention-deficit/hyperactivity disorder and bipolar disorder. Biol Psychiatry. 2003 Jul 01; 54(1):9-16. View abstract
  72. Ulbricht C, Basch E, Ulbricht C, Sollars D, Hammerness P, Hashmi S. Wild yam (Dioscoreaceae). J Herb Pharmacother. 2003; 3(4):77-91. View abstract
  73. Ulbricht C, Basch E, Vora M, Sollars D, Rogers A, Basch S, Smith M, Moffet H, Hammerness P. Chaparral monograph:a clinical decision support tool. J Herb Pharmacother. 2003; 3(1):121-33. View abstract
  74. Basch E, Ulbricht C, Hammerness P, Vora M. Marshmallow (Althaea officinalis L.) monograph. J Herb Pharmacother. 2003; 3(3):71-81. View abstract
  75. Hammerness P, Parada H, Abrams A. Linezolid: MAOI activity and potential drug interactions. Psychosomatics. 2002 May-Jun; 43(3):248-9. View abstract
  76. Hammerness P, Ulbricht C, Barrette EP, Boon H, Szapary P, Sollars D, Smith M, Tsourounis C, Bent S, Basch E. Shark cartilage monograph: a clinical decision support tool. J Herb Pharmacother. 2002; 2(2):71-93. View abstract
  77. Basch E, Ulbricht C, Hammerness P, Tsouronis C, Sollars D, Rogers A, Basch S, Bent S, Boon H, Ernst E. Kava monograph: a clinical decision support tool. J Herb Pharmacother. 2002; 2(4):65-91. View abstract
  78. Nugent WC, Edney MT, Hammerness PG, Dain BJ, Maurer LH, Rigas JR. Non-small cell lung cancer at the extremes of age: impact on diagnosis and treatment. Ann Thorac Surg. 1997 Jan; 63(1):193-7. View abstract
  79. Pollack MH, Otto MW, Kaspi SP, Hammerness PG, Rosenbaum JF. Cognitive behavior therapy for treatment-refractory panic disorder. J Clin Psychiatry. 1994 May; 55(5):200-5. View abstract
  80. Lafer B, Fava M, Hammerness P, Rosenbaum JF. The influence of DST and TRH test administration on depression assessments: a controlled study. Biol Psychiatry. 1993 Nov 01; 34(9):650-3. View abstract
  81. Pollack MH, Hammerness P. Adjunctive yohimbine for treatment in refractory depression. Biol Psychiatry. 1993 Feb 01; 33(3):220-1. View abstract
  82. Pollack MH, Reiter S, Hammerness P. Genitourinary and sexual adverse effects of psychotropic medication. Int J Psychiatry Med. 1992; 22(4):305-27. View abstract